Real-World check: is heart drug verquvo safe for korean patients?

NCT ID NCT06148935

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study observes 1350 Korean adults with chronic heart failure who are prescribed Verquvo by their doctors. Researchers will track side effects and heart-related events over up to 12 months to see how safe and effective the drug is in everyday use. No experimental treatments are given—just routine care and data collection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION

Contacts and locations

Locations

Many Locations
RECRUITING

Multiple Locations, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.